BURLINGTON, Mass.--(BUSINESS WIRE)--Aug. 30, 2018--
ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, CEO, Peter
Lawrence, President and COO, Brian Schwartz, CMO and Head of R&D and
Marc Schegerin, Senior Vice President and Head of Strategy, Finance and
Communication, will participate in Citi’s 13th Annual Biotech Conference
on September 6, 2018, at the Four Seasons Hotel in Boston, MA.
ArQule is a biopharmaceutical company engaged in the research and
development of targeted therapeutics to treat cancers and rare diseases.
ArQule’s mission is to discover, develop and commercialize novel small
molecule drugs in areas of high unmet need that will dramatically extend
and improve the lives of our patients. Our clinical-stage pipeline
consists of five drug candidates, all of which are in targeted,
biomarker-defined patient populations, making ArQule a leader among
companies our size in precision medicine. ArQule’s pipeline includes:
ARQ 531, an orally bioavailable, potent and reversible inhibitor of both
wild type and C481S-mutant BTK, in Phase 1 for patients with B-cell
malignancies refractory to other therapeutic options; Miransertib (ARQ
092), a selective inhibitor of the AKT serine/threonine kinase, in a
Phase 1/2 company-sponsored study for Overgrowth Diseases, in a Phase 1
study for ultra-rare Proteus syndrome conducted by the National
Institutes of Health (NIH), and in Phase 1b in combination with the
hormonal therapy, anastrozole, in patients with advanced endometrial
cancer; ARQ 751, a next generation AKT inhibitor, in Phase 1 for
patients with AKT1 and PI3K mutations; Derazantinib, a multi-kinase
inhibitor designed to preferentially inhibit the fibroblast growth
factor receptor (FGFR) family, in a registrational trial for iCCA; and
ARQ 761, a β-lapachone analog being evaluated as a promoter of
NQO1-mediated programmed cancer cell necrosis, in Phase 1/2 in multiple
oncology indications in partnership with the University of Texas
Southwestern Medical Center. ArQule’s current discovery efforts are
focused on the identification and development of novel kinase
inhibitors, leveraging the Company’s proprietary library of compounds.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180830005758/en/
Source: ArQule, Inc.
Marc Schegerin, M.D.
Vice President,Head of Strategy, Finance and Communication
LifeSci Public Relations
Allison Blum, Ph.D.,